SG195290A1 - Therapeutic agents for regulating serum phosphorus - Google Patents
Therapeutic agents for regulating serum phosphorusInfo
- Publication number
- SG195290A1 SG195290A1 SG2013089594A SG2013089594A SG195290A1 SG 195290 A1 SG195290 A1 SG 195290A1 SG 2013089594 A SG2013089594 A SG 2013089594A SG 2013089594 A SG2013089594 A SG 2013089594A SG 195290 A1 SG195290 A1 SG 195290A1
- Authority
- SG
- Singapore
- Prior art keywords
- serum phosphorus
- compound
- therapeutic agents
- subunits
- administered
- Prior art date
Links
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 title abstract 3
- 229910052698 phosphorus Inorganic materials 0.000 title abstract 3
- 239000011574 phosphorus Substances 0.000 title abstract 3
- 210000002966 serum Anatomy 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002092 calcimimetic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 abstract 1
- 229960003315 cinacalcet Drugs 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494874P | 2011-06-08 | 2011-06-08 | |
| PCT/US2012/041759 WO2012170955A1 (en) | 2011-06-08 | 2012-06-08 | Therapeutic agents for regulating serum phosphorus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG195290A1 true SG195290A1 (en) | 2013-12-30 |
Family
ID=46321485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013089594A SG195290A1 (en) | 2011-06-08 | 2012-06-08 | Therapeutic agents for regulating serum phosphorus |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8969299B2 (enExample) |
| EP (1) | EP2717896B1 (enExample) |
| JP (1) | JP5982473B2 (enExample) |
| KR (1) | KR102057508B1 (enExample) |
| CN (1) | CN103857405B (enExample) |
| AU (1) | AU2012267470C1 (enExample) |
| BR (1) | BR112013031539A2 (enExample) |
| CA (1) | CA2837445C (enExample) |
| CY (1) | CY1118430T1 (enExample) |
| DK (1) | DK2717896T3 (enExample) |
| ES (1) | ES2607986T3 (enExample) |
| HR (1) | HRP20161566T1 (enExample) |
| HU (1) | HUE032087T2 (enExample) |
| LT (1) | LT2717896T (enExample) |
| MX (1) | MX337613B (enExample) |
| PL (1) | PL2717896T3 (enExample) |
| PT (1) | PT2717896T (enExample) |
| RS (1) | RS55503B1 (enExample) |
| RU (1) | RU2612912C2 (enExample) |
| SG (1) | SG195290A1 (enExample) |
| SI (1) | SI2717896T1 (enExample) |
| SM (2) | SMT201700081T1 (enExample) |
| WO (1) | WO2012170955A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2459208T (pt) | 2009-07-29 | 2017-01-03 | Kai Pharmaceuticals Inc | Agentes terapêuticos para redução dos niveis de hormona paratiroideia |
| LT3013318T (lt) * | 2013-06-28 | 2017-09-11 | Amgen Inc. | Stabili amg 416 (velcalcetide) kompozicija |
| RU2686086C1 (ru) * | 2018-05-17 | 2019-04-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом |
| CN114222578B (zh) * | 2019-12-09 | 2024-06-25 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物及其应用 |
| WO2022052471A1 (zh) * | 2020-09-10 | 2022-03-17 | 陕西麦科奥特科技有限公司 | 双特异性融合多肽化合物 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| AU9131091A (en) | 1990-11-07 | 1992-06-11 | Scripps Research Institute, The | Peptides that inhibit platelet binding of adhesion molecules |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| WO1995006056A1 (en) | 1993-08-20 | 1995-03-02 | University Of Medicine & Dentistry Of New Jersey | Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same |
| CA2145214A1 (en) | 1995-02-28 | 1996-08-29 | Rick E. Preddie | Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans |
| US5688489A (en) | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| US5895368A (en) * | 1996-09-23 | 1999-04-20 | Medisystems Technology Corporation | Blood set priming method and apparatus |
| US6165977A (en) | 1996-10-18 | 2000-12-26 | Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific activators of protein kinase C methods and compositions |
| US6258774B1 (en) | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| JP2000336099A (ja) | 1999-05-27 | 2000-12-05 | Sekisui Chem Co Ltd | ペプチド及びｃ型肝炎抗体検出用試薬 |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| AU7895601A (en) | 2000-07-18 | 2002-01-30 | Bone Care Int Inc | Stabilized 1alpha-hydroxy vitamin d |
| US20080249016A1 (en) | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
| US20020168354A1 (en) | 2000-11-10 | 2002-11-14 | Daria Mochly-Rosen | psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia |
| AU2002226061B2 (en) | 2001-01-18 | 2007-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of delta PKC |
| WO2002062396A2 (en) | 2001-02-08 | 2002-08-15 | University Of Medicine And Dentistry Of New Jersey | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates |
| US20030036627A1 (en) | 2001-02-16 | 2003-02-20 | Montelaro Ronald C. | Virus derived antimicrobial peptides |
| EP1363934B1 (en) | 2001-02-23 | 2014-10-08 | Polyphor Ltd. | Template-fixed peptidomimetics with antimicrobial activity |
| JP2005287302A (ja) | 2002-04-03 | 2005-10-20 | Haruhiko Fujiwara | ポリペプチドの架橋方法 |
| WO2004039940A2 (en) | 2002-05-14 | 2004-05-13 | Bristol-Myers Squibb Company | Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof |
| WO2004093821A2 (en) | 2003-04-22 | 2004-11-04 | Hawaii Biotech, Inc. | Treatment of anthrax infection using inhibitors of lethal factor protease activity |
| AU2004291277A1 (en) | 2003-11-05 | 2005-06-02 | Intercell Ag | Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens |
| CA2549052A1 (en) | 2003-12-11 | 2005-06-30 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific antagonists of protein kinase c |
| WO2005072340A2 (en) | 2004-01-27 | 2005-08-11 | Compugen Ltd. | Novel polynucleotides encoding polypeptides and methods using same |
| US7265092B2 (en) | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| ITME20040015A1 (it) * | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
| EP1937064A4 (en) | 2005-08-30 | 2009-09-16 | Acologix Inc | REGULATION OF MINERALS AND SKELETAL METABOLISM |
| WO2007038172A2 (en) | 2005-09-23 | 2007-04-05 | Nitto Denko Corporation | Guanidinium carriers |
| KR101552843B1 (ko) | 2006-11-16 | 2015-09-14 | 카이 파마슈티컬즈 | 부갑상선 기능항진증 및 고칼슘혈증 장애의 치료를 위한 폴리양이온성 칼슘 조절제 펩타이드 |
| CN103524623A (zh) | 2007-01-19 | 2014-01-22 | 凯制药公司 | 肽组合物的修饰以提高稳定性和递送效率 |
| JP5697450B2 (ja) | 2007-10-02 | 2015-04-08 | マリーナ バイオテック，インコーポレイテッド | 核酸の送達のためのリポペプチド |
| WO2009075773A2 (en) | 2007-12-07 | 2009-06-18 | Goldstein Steven A | Identification of toxin ligands |
| PT2459208T (pt) * | 2009-07-29 | 2017-01-03 | Kai Pharmaceuticals Inc | Agentes terapêuticos para redução dos niveis de hormona paratiroideia |
-
2012
- 2012-06-08 SM SM20170081T patent/SMT201700081T1/it unknown
- 2012-06-08 PT PT127289072T patent/PT2717896T/pt unknown
- 2012-06-08 HR HRP20161566TT patent/HRP20161566T1/hr unknown
- 2012-06-08 US US13/492,778 patent/US8969299B2/en active Active
- 2012-06-08 RU RU2013157928A patent/RU2612912C2/ru active IP Right Revival
- 2012-06-08 JP JP2014514910A patent/JP5982473B2/ja active Active
- 2012-06-08 DK DK12728907.2T patent/DK2717896T3/en active
- 2012-06-08 CN CN201280038112.5A patent/CN103857405B/zh active Active
- 2012-06-08 ES ES12728907.2T patent/ES2607986T3/es active Active
- 2012-06-08 CA CA2837445A patent/CA2837445C/en active Active
- 2012-06-08 AU AU2012267470A patent/AU2012267470C1/en active Active
- 2012-06-08 HU HUE12728907A patent/HUE032087T2/en unknown
- 2012-06-08 EP EP12728907.2A patent/EP2717896B1/en active Active
- 2012-06-08 KR KR1020137034736A patent/KR102057508B1/ko active Active
- 2012-06-08 WO PCT/US2012/041759 patent/WO2012170955A1/en not_active Ceased
- 2012-06-08 MX MX2013014249A patent/MX337613B/es active IP Right Grant
- 2012-06-08 SG SG2013089594A patent/SG195290A1/en unknown
- 2012-06-08 BR BR112013031539A patent/BR112013031539A2/pt not_active Application Discontinuation
- 2012-06-08 LT LTEP12728907.2T patent/LT2717896T/lt unknown
- 2012-06-08 RS RS20161021A patent/RS55503B1/sr unknown
- 2012-06-08 PL PL12728907T patent/PL2717896T3/pl unknown
- 2012-06-08 SI SI201230784A patent/SI2717896T1/sl unknown
-
2016
- 2016-11-24 CY CY20161101220T patent/CY1118430T1/el unknown
-
2017
- 2017-02-06 SM SM201700081T patent/SMT201700081B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012267470B2 (en) | 2017-06-15 |
| JP5982473B2 (ja) | 2016-08-31 |
| AU2012267470C1 (en) | 2017-09-21 |
| HRP20161566T1 (hr) | 2017-02-24 |
| RU2013157928A (ru) | 2015-07-20 |
| MX337613B (es) | 2016-03-10 |
| WO2012170955A1 (en) | 2012-12-13 |
| CY1118430T1 (el) | 2017-06-28 |
| US8969299B2 (en) | 2015-03-03 |
| CA2837445A1 (en) | 2012-12-13 |
| HUE032087T2 (en) | 2017-08-28 |
| RS55503B1 (sr) | 2017-05-31 |
| RU2612912C2 (ru) | 2017-03-13 |
| PT2717896T (pt) | 2016-12-23 |
| CN103857405B (zh) | 2015-12-02 |
| LT2717896T (lt) | 2017-02-27 |
| SI2717896T1 (sl) | 2017-04-26 |
| DK2717896T3 (en) | 2016-12-19 |
| PL2717896T3 (pl) | 2017-05-31 |
| KR102057508B1 (ko) | 2019-12-19 |
| SMT201700081B (it) | 2017-03-08 |
| CA2837445C (en) | 2022-10-04 |
| SMT201700081T1 (it) | 2017-03-08 |
| KR20140035456A (ko) | 2014-03-21 |
| EP2717896A1 (en) | 2014-04-16 |
| US20130150301A1 (en) | 2013-06-13 |
| JP2014522414A (ja) | 2014-09-04 |
| BR112013031539A2 (pt) | 2019-07-30 |
| EP2717896B1 (en) | 2016-08-24 |
| CN103857405A (zh) | 2014-06-11 |
| ES2607986T3 (es) | 2017-04-05 |
| MX2013014249A (es) | 2014-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191162T1 (hr) | Postupci liječenja ankilozantnog spondilitisa uporabom anti-il-17 protutijela | |
| EP4545143A3 (en) | Early intervention methods to prevent or ameliorate toxicity | |
| MX345747B (es) | Dispositivo de inyección automático portable. | |
| EA201591404A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
| MX357551B (es) | Metodos y composiciones para el tratamiento de trastorno por deficit de atencion. | |
| EA201591403A1 (ru) | Спиролактамные модуляторы рецептора nmda и их применение | |
| IN2014KN00996A (enExample) | ||
| EA201591405A1 (ru) | Спиролактамные модуляторы nmda-рецептора и их применение | |
| BR112012031359A2 (pt) | sistema e método de planejamento e monitoramento da utilização de doses múltiplas de radiofármacos em injetores de radiofármacos | |
| MX2015000428A (es) | Composiciones y metodos para regular celulas t car. | |
| IN2014MN00333A (enExample) | ||
| EA201591401A1 (ru) | Спиролактамные модуляторы nmda-рецептора и их применение | |
| BR112014030404A2 (pt) | proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento | |
| SG195290A1 (en) | Therapeutic agents for regulating serum phosphorus | |
| UA108885C2 (uk) | Композиція рисперидону для ін'єкційної депо-форми | |
| NZ598722A (en) | Methods for treating psoriasis | |
| MY160979A (en) | A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders | |
| UA109803C2 (xx) | (ПІРИДИН-4-ІЛ)БЕНЗИЛАМІДИ ЯК АЛОСТЕРИЧНІ МОДУЛЯТОРИ АЛЬФА-7 nAChR | |
| EA201591188A1 (ru) | Доставка глатирамера ацетата через слизистую оболочку | |
| MX2015007402A (es) | Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos. | |
| WO2014062228A8 (en) | An improved nanovector based drug delivery system for overcoming drug resistance | |
| PH12013501896A1 (en) | Use of a sprayable composition comprising ambroxol | |
| WO2012134590A3 (en) | Calcium supplement | |
| RU2011108787A (ru) | Способ лечения больных красным плоским лишаем слизистой полости рта | |
| BRPI0906945A2 (pt) | (e)-n-{3-[1-(8-flúor-11h-10-oxa-1-aza-dibenzo[a,d]ciclo-h epten-5-ilideno)-propil]-fenil}-metinsulfona amida como modulador de receptores de glicocorticoides para o tratamento de reumatoide. |